In that light, Watson et al., found an increase in plasma NFL levels in AD patients with PSEN1 or APP mutations suggesting that NFL may assist as an initial diagnostic biomarker for early-onset AD, as plasma NFL concentrations were found to be elevated before the manifestation of symptoms (preclinical and prodromal AD) and corresponded with the severity stage of the disease [47]. Here, NEFL is linked to Alzheimer disease.